Risk and outcome in metastatic malignant melanoma patients receiving DTIC, cisplatin, BCNU and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha2a
Open Access
- 1 October 1998
- journal article
- clinical trial
- Published by Springer Nature in British Journal of Cancer
- Vol. 78 (8) , 1076-1080
- https://doi.org/10.1038/bjc.1998.630
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon alpha and chemotherapy.1997
- Outpatient chemoimmunotherapy for the treatment of metastatic melanoma.1997
- Subcutaneous recombinant interleukin-2 plus chemotherapy with cisplatin and dacarbazine in metastatic melanomaEuropean Journal Of Cancer, 1996
- Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.Journal of Clinical Oncology, 1996
- Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-α after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifenEuropean Journal Of Cancer, 1995
- Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma.Journal of Clinical Oncology, 1994
- Treatment of 283 Consecutive Patients With Metastatic Melanoma or Renal Cell Cancer Using High-Dose Bolus Interleukin 2JAMA, 1994
- Sequential chemoimmunotherapy in the treatment of metastatic melanoma.1992
- Effective chemotherapy for melanoma after treatment with interleukin-2Cancer, 1992
- Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma.1984